nach oben

Inflammation

Erschienen in:

26.09.2017 | ORIGINAL ARTICLE

Anti-IL-33 Antibody Has a Therapeutic Effect in an Atopic Dermatitis Murine Model Induced by 2, 4-Dinitrochlorobenzene

verfasst von: Ge Peng, Zhenzhen Mu, Lixia Cui, Pengyue Liu, Ying Wang, Wenqing Wu, Xiuping Han

Erschienen in: Inflammation | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

IL-33 is a new member of the IL-1 family that plays a role in allergic disease. In this study, we evaluated the potential on the inhibition of atopic dermatitis (AD) of anti-mouse IL-33 antibody (αIL-33Ab) using 2, 4-dinitrochlorobenzene (DNCB)-induced AD mice model. We treated mice with αIL-33Ab via subcutaneous injection of each DNCB treatment 1 h later from day 1 to day 33 for 14 times. A control group received tacrolimus. Skin lesion and scratching behavior were compared. Ear thickness, dermatitis score, eosinophils and mast cells infiltration, and serum IgE levels were also analyzed. Correlations between serum IL-33 as well as soluble(s) ST2 and AD disease activity index in human AD were also investigated. DNCB-induced AD-like mice treated with αIL-33Ab showed improved AD-like symptoms. Eosinophils and mast cells infiltration and serum IgE levels were also significantly reduced by αIL-33Ab. Our study suggests that blockade of IL-33 has a curative effect on AD.

Nur mit Berechtigung zugänglich

Weidinger, S., and N. Novak. 2016. Atopic dermatitis. Lancet 387 (10023): 1109–1122. https://doi.org/10.1016/S0140-6736(15)00149-X.CrossRefPubMed

Karuppagounder, V., S. Arumugam, R.A. Thandavarayan, V. Pitchaimani, R. Sreedhar, R. Afrin, M. Harima, H. Suzuki, M. Nomoto, S. Miyashita, K. Suzuki, M. Nakamura, K. Ueno, and K. Watanabe. 2015. Tannic acid modulates NF휅B signaling pathway and skin inflammation in NC/Nga mice through PPAR훾 expression. Cytokine 76 (2): 206–213. https://doi.org/10.1016/j.cyto.2015.05.016.CrossRefPubMed

Liu, F.T., H. Goodarzi, and H.Y. Chen. 2011. IgE, mast cells, and eosinophils in atopic dermatitis. Clinical Reviews in Allergy & Immunology 41 (3): 298–310. https://doi.org/10.1007/s12016-011-8252-4.CrossRef

Numerof, R.P., and K. Asadullah. 2006. Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis. BioDrugs 20 (2): 93–103.CrossRefPubMed

Molfino, N.A., D. Gossage, R. Kolbeck, J.M. Parker, and G.P. Geba. 2012. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clinical and Experimental Allergy 42 (5): 712–737. https://doi.org/10.1111/j.1365-2222.2011.03854.x.CrossRefPubMed

Di Lernia, V. 2015. Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach. Expert Opinion on Therapeutic Targets 19 (1): 87–96. https://doi.org/10.1517/14728222.2014.965682.CrossRefPubMed

Chow, J.Y., C.K. Wong, P.F. Cheung, and C.W. Lam. 2010. Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cellular & Molecular Immunology 7 (1): 26–34. https://doi.org/10.1038/cmi.2009.106.CrossRef

Olivry, T., D. Mayhew, J.S. Paps, K.E. Linder, C. Peredo, D. Rajpal, H. Hofland, and J. Cote-Sierra. 2016. Early activation of Th2/Th22 inflammatory and pruritogenic pathways in acute canine atopic dermatitis skin lesions. The Journal of Investigative Dermatology 136 (10): 1961–1969. https://doi.org/10.1016/j.jid.2016.05.117.CrossRefPubMed

Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T.K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, D.M. Gorman, J.F. Bazan, and R.A. Kastelein. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (5): 479–490.CrossRefPubMed

10.

Liew, F.Y., N.I. Pitman, and I.B. McInnes. 2010. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nature Reviews. Immunology 10 (2): 103–110. https://doi.org/10.1038/nri2692.CrossRefPubMed

11.

Saluja, R., M.E. Ketelaar, T. Hawro, M.K. Church, M. Maurer, and M.C. Nawijn. 2015. The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Molecular Immunology 63 (1): 80–85. https://doi.org/10.1016/j.molimm.2014.06.018.CrossRefPubMed

12.

Iikura, M., H. Suto, N. Kajiwara, K. Oboki, T. Ohno, Y. Okayama, H. Saito, S.J. Galli, and S. Nakae. 2007. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Laboratory Investigation 87 (10): 971–978.CrossRefPubMed

13.

Pecaric-Petkovic, T., S.A. Didichenko, S. Kaempfer, N. Spiegl, and C.A. Dahinden. 2009. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 113 (7): 1526–1534. https://doi.org/10.1182/blood-2008-05-157818.CrossRefPubMedPubMedCentral

14.

Kroeger, K.M., B.M. Sullivan, and R.M. Locksley. 2009. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. Journal of Leukocyte Biology 86 (4): 769–778. https://doi.org/10.1189/jlb.0708452.CrossRefPubMedPubMedCentral

15.

Saluja, R., A. Zoltowska, M.E. Ketelaar, and G. Nilsson. 2016. IL-33 and thymic stromal lymphopoietin in mast cell functions. European Journal of Pharmacology 778: 68–76. https://doi.org/10.1016/j.ejphar.2015.04.047.CrossRefPubMed

16.

Li, C., I. Maillet, C. Mackowiak, C. Viala, F. Di Padova, M. Li, D. Togbe, V. Quesniaux, Y. Lai, and B. Ryffel. 2017. Experimental atopic dermatitis depends on IL-33R signaling via MyD88 in dendritic cells. Cell Death & Disease 8 (4): e2735. https://doi.org/10.1038/cddis.2017.90.CrossRef

17.

Mizutani, N., T. Nabe, and S. Yoshino. 2013. Interleukin-33 and alveolar macrophages contribute to the mechanisms underlying the exacerbation of IgE-mediated airway inflammation and remodelling in mice. Immunology 139 (2): 205–218. https://doi.org/10.1111/imm.12071.CrossRefPubMedPubMedCentral

18.

Hanifin, J.M., and G. Rajka. 1980. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 92 (Suppl): 44–47.

19.

Severity scoring of atopic dermatitis: the SCORAD index. 1993. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 186(1):23–31.

20.

Kilkenny, C., W. Browne, I.C. Cuthill, M. Emerson, D.G. Altman, and NC3Rs Reporting Guidelines Working Group. 2010. Animal research: reporting in vivo experiments: the ARRIVE guidelines. British Journal of Pharmacology 160 (7): 1577–1579. https://doi.org/10.1111/j.1476-5381.2010.00872.x.CrossRefPubMedPubMedCentral

21.

McGrath, J., G. Drummond, E. Mclachlan, C. Kilkenny, and C.L. Wainwright. 2010. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. British Journal of Pharmacology 160 (7): 1573–1576. https://doi.org/10.1111/j.1476-5381.2010.00873.x.CrossRefPubMedPubMedCentral

22.

Kim, H., J.R. Kim, H. Kang, J. Choi, H. Yang, P. Lee, J. Kim, and K.W. Lee. 2014. 7,8,4′-Trihydroxyisoflavone attenuates DNCB-induced atopic dermatitis-like symptoms in NC/Nga mice. PLoS One 9 (8): e104938. https://doi.org/10.1371/journal.pone.0104938.CrossRefPubMedPubMedCentral

23.

Yamashita, H., T. Makino, H. Mizukami, and M. Nose. 2007. Pharmacological characterization of a chronic pruritus model induced by multiple application of 2, 4, 6-trinitrochlorobenzene in NC mice. European Journal of Pharmacology 563: 233–239.CrossRefPubMed

24.

Leung, D.Y., R.L. Hirsch, L. Schneider, C. Moody, R. Takaoka, S.H. Li, L.A. Meyerson, S.G. Mariam, G. Goldstein, and J.M. Hanifin. 1990. Thymopentin therapy reduces the clinical severity of atopic dermatitis. The Journal of Allergy and Clinical Immunology 85 (5): 927–933.CrossRefPubMed

25.

Jo, S., J. Ryu, H. Kim, M. Kim, M.H. Ryu, H. Kim, and S.I. Cho. 2015. Anti-inflammatory effects of Sanguisorbae Radix on contact dermatitis induced by dinitrofluorobenzene in mice. Chinese Journal of Integrative Medicine. https://doi.org/10.1007/s11655-015-2148-8.

26.

Lu, Y., J.H. Yang, X. Li, K. Hwangbo, S.L. Hwang, Y. Taketomi, M. Murakami, Y.C. Chang, C.H. Kim, J.K. Son, and H.W. Chang. 2011. Emodin, a naturally occurring anthraquinone derivative, suppresses IgE-mediated anaphylactic reaction and mast cell activation. Biochemical Pharmacology 82 (11): 1700–1708. https://doi.org/10.1016/j.bcp.2011.08.022.CrossRefPubMed

27.

Brandt EB, Sivaprasad U. 2011. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol. 2(3). doi: https://doi.org/10.4172/2155-9899.1000110.

28.

Lu, Y., Y. Li, M. Jin, J.H. Yang, X. Li, G.H. Chao, H.H. Park, Y.N. Park, J.K. Son, E. Lee, and H.W. Chang. 2012. Inula japonica extract inhibits mast cell-mediated allergic reaction and mast cell activation. Journal of Ethnopharmacology 143 (1): 151–157. https://doi.org/10.1016/j.jep.2012.06.015.CrossRefPubMed

29.

Kawakami, T., T. Ando, M. Kimura, B.S. Wilson, and Y. Kawakami. 2009. Mast cells in atopic dermatitis. Current Opinion in Immunology 21 (6): 666–678. https://doi.org/10.1016/j.coi.2009.09.006.CrossRefPubMedPubMedCentral

30.

Leung, D.Y. 2000. Atopic dermatitis: new insights and opportunities for therapeutic intervention. The Journal of Allergy and Clinical Immunology 105 (5): 860–876. https://doi.org/10.1067/mai.2000.106484.CrossRefPubMed

31.

Beck, L.A., and D.Y. Leung. 2000. Allergen sensitization through the skin induces systemic allergic responses. The Journal of Allergy and Clinical Immunology 106 (5 Suppl): S258–S263.CrossRefPubMed

32.

Tamagawa-Mineoka, R., Y. Okuzawa, K. Masuda, and N. Katoh. 2014. Increased serum levels of interleukin 33 in patients with atopic dermatitis. Journal of the American Academy of Dermatology 70 (5): 882–888. https://doi.org/10.1016/j.jaad.2014.01.867.CrossRefPubMed

33.

Savinko, T., S. Matikainen, U. Saarialho-Kere, M. Lehto, G. Wang, S. Lehtimäki, P. Karisola, T. Reunala, H. Wolff, A. Lauerma, and H. Alenius. 2012. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. The Journal of Investigative Dermatology 132 (5): 1392–1400. https://doi.org/10.1038/jid.2011.446.CrossRefPubMed

34.

Vocca, L., C. Di Sano, C.G. Uasuf, A. Sala, L. Riccobono, S. Gangemi, G.D. Albano, A. Bonanno, R. Gagliardo, and M. Profita. 2015. IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases. Immunobiology 220 (8): 954–963. https://doi.org/10.1016/j.imbio.2015.02.005.CrossRefPubMed

35.

Hamzaoui, A., A. Berraies, W. Kaabachi, M. Haifa, J. Ammar, and H. Kamel. 2013. Induced sputum levels of IL-33 and soluble ST2 in young asthmatic children. The Journal of Asthma 50 (8): 803–809. https://doi.org/10.3109/02770903.2013.816317.CrossRefPubMed

36.

Nygaard, U., M. Hvid, C. Johansen, M. Buchner, R. Fölster-Holst, M. Deleuran, and C. Vestergaard. 2016. TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis. Journal of the European Academy of Dermatology and Venereology 30 (11): 1930–1938. https://doi.org/10.1111/jdv.13679.PubMed

37.

Hayakawa, H., M. Hayakawa, A. Kume, and S. Tominaga. 2007. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. The Journal of Biological Chemistry 282: 26369–26380.CrossRefPubMed

Titel: Anti-IL-33 Antibody Has a Therapeutic Effect in an Atopic Dermatitis Murine Model Induced by 2, 4-Dinitrochlorobenzene
verfasst von: Ge Peng
Zhenzhen Mu
Lixia Cui
Pengyue Liu
Ying Wang
Wenqing Wu
Xiuping Han
Publikationsdatum: 26.09.2017
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 1/2018
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-017-0673-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Anti-IL-33 Antibody Has a Therapeutic Effect in an Atopic Dermatitis Murine Model Induced by 2, 4-Dinitrochlorobenzene

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

CD80 Regulates Th17 Cell Differentiation in Coxsackie Virus B3-Induced Acute Myocarditis

Elevated Levels of ADMA Are Associated with Lower DDAH2 and Higher PRMT1 in LPS-Induced Endometritis Rats

Experimental Study of the Protective Effect of Simvastatin on Lung Injury in Rats with Sepsis

The Falconoid Luteolin Mitigates the Myocardial Inflammatory Response Induced by High-Carbohydrate/High-Fat Diet in Wistar Rats

MicroRNA-155 Inhibits Polarization of Macrophages to M2-Type and Suppresses Choroidal Neovascularization

Saikosaponin a Ameliorates LPS-Induced Acute Lung Injury in Mice

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin